PMID- 16772808
OWN - NLM
STAT- MEDLINE
DCOM- 20060727
LR  - 20141120
IS  - 0362-5664 (Print)
IS  - 0362-5664 (Linking)
VI  - 29
IP  - 3
DP  - 2006 May-Jun
TI  - The controversy concerning plasma homocysteine in Parkinson disease patients 
      treated with levodopa alone or with entacapone: effects of vitamin status.
PG  - 106-11
AB  - Levodopa treatment of Parkinson disease results in hyperhomocysteinemia (HHcy) as 
      a consequence of levodopa methylation by catechol-O-methyltransferase (COMT). 
      Although inhibition of COMT should theoretically prevent or reduce 
      levodopa-induced HHcy, results from several prospective studies are conflicting. 
      Our review of these studies suggests that the ability of COMT inhibition to 
      reduce or prevent levodopa-induced HHcy in Parkinson disease patients may be 
      attributed to differences in the vitamin status of the study participants. In 
      patients with low or low-normal folate levels, levodopa administration is 
      associated with a greater increase in homocysteine and concomitant entacapone 
      administration is associated with a greater reduction in homocysteine.
FAU - Zesiewicz, Theresa A
AU  - Zesiewicz TA
AD  - Parkinson's Disease and Movement Disorders Center, University of South Florida, 
      Tampa, 33612, USA. tzesiewi@hsc.usf.edu
FAU - Wecker, Lynn
AU  - Wecker L
FAU - Sullivan, Kelly L
AU  - Sullivan KL
FAU - Merlin, Lisa R
AU  - Merlin LR
FAU - Hauser, Robert A
AU  - Hauser RA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Clin Neuropharmacol
JT  - Clinical neuropharmacology
JID - 7607910
RN  - 0 (Catechol O-Methyltransferase Inhibitors)
RN  - 0 (Catechols)
RN  - 0 (Nitriles)
RN  - 0 (Vitamins)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 46627O600J (Levodopa)
RN  - 4975G9NM6T (entacapone)
RN  - 935E97BOY8 (Folic Acid)
RN  - EC 2.1.1.6 (Catechol O-Methyltransferase)
RN  - P6YC3EG204 (Vitamin B 12)
SB  - IM
MH  - Catechol O-Methyltransferase/blood
MH  - Catechol O-Methyltransferase Inhibitors
MH  - Catechols/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Folic Acid/blood
MH  - Homocysteine/*blood
MH  - Humans
MH  - Levodopa/adverse effects/*therapeutic use
MH  - Nitriles
MH  - Parkinson Disease/*blood/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Vitamin B 12/blood
MH  - Vitamins/*blood
RF  - 21
EDAT- 2006/06/15 09:00
MHDA- 2006/07/28 09:00
CRDT- 2006/06/15 09:00
PHST- 2006/06/15 09:00 [pubmed]
PHST- 2006/07/28 09:00 [medline]
PHST- 2006/06/15 09:00 [entrez]
AID - 00002826-200605000-00002 [pii]
AID - 10.1097/01.WNF.0000220817.94102.95 [doi]
PST - ppublish
SO  - Clin Neuropharmacol. 2006 May-Jun;29(3):106-11. doi: 
      10.1097/01.WNF.0000220817.94102.95.